You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NameMethsuximide
Accession NumberDB05246
TypeSmall Molecule
GroupsApproved
DescriptionMesuximide (or methsuximide) is an anticonvulsant medication. It is sold by Pfizer under the name Petinutin. [Wikipedia]
Structure
Thumb
Synonyms
(RS)-1,3-Dimethyl-3-phenyl-2,5-pyrrolidindion
1,3-Dimethyl-3-phenyl-2,5-dioxopyrrolidine
1,3-Dimethyl-3-phenyl-2,5-pyrrolidinedione
1,3-Dimethyl-3-phenyl-pyrrolidin-2,5-dione
1,3-Dimethyl-3-phenylsuccinimide
Alpha-methyl-alpha-phenyl n-methyl succinimide
Alpha-methylphensuximide
Celontin
Mesuximida
Mesuximide
Mesuximidum
Methsuximid
Metosuccimmide
Metsuccimide
N-methyl-alpha-methyl-alpha-phenylsuccinimide
N,2-Dimethyl-2-phenylsuccinimide
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Celontincapsule300 mg/1oralParke Davis Div Of Pfizer Inc1957-02-08Not applicableUs
Celontin Cap 300mgcapsule300 mgoralErfa Canada 2012 Inc1957-12-312015-06-05Canada
Approved Generic Prescription ProductsNot Available
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
PetinutinNot Available
Brand mixturesNot Available
SaltsNot Available
Categories
UNII0G76K8X6C0
CAS number77-41-8
WeightAverage: 203.2371
Monoisotopic: 203.094628665
Chemical FormulaC12H13NO2
InChI KeyInChIKey=AJXPJJZHWIXJCJ-UHFFFAOYSA-N
InChI
InChI=1S/C12H13NO2/c1-12(9-6-4-3-5-7-9)8-10(14)13(2)11(12)15/h3-7H,8H2,1-2H3
IUPAC Name
1,3-dimethyl-3-phenylpyrrolidine-2,5-dione
SMILES
CN1C(=O)CC(C)(C1=O)C1=CC=CC=C1
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as phenylpyrrolidines. These are polycyclic aromatic compounds containing a benzene ring linked to a pyrrolidine ring through a CC or CN bond. Pyrrolidine is a five-membered saturated aliphatic heterocycle with one nitrogen atom and four carbon atoms.
KingdomOrganic compounds
Super ClassOrganoheterocyclic compounds
ClassPyrrolidines
Sub ClassPhenylpyrrolidines
Direct ParentPhenylpyrrolidines
Alternative Parents
Substituents
  • 3-phenylpyrrolidine
  • Dicarboximide
  • Benzenoid
  • N-alkylpyrrolidine
  • 2-pyrrolidone
  • Pyrrolidone
  • Carboxylic acid imide, n-substituted
  • Monocyclic benzene moiety
  • Pyrrole
  • Carboxylic acid imide
  • Tertiary amine
  • Lactam
  • Carboxamide group
  • Azacycle
  • Carboxylic acid derivative
  • Hydrocarbon derivative
  • Organooxygen compound
  • Organonitrogen compound
  • Carbonyl group
  • Amine
  • Aromatic heteromonocyclic compound
Molecular FrameworkAromatic heteromonocyclic compounds
External DescriptorsNot Available
Pharmacology
IndicationFor the control of absence (petit mal) seizures that are refractory to other drugs.
PharmacodynamicsUsed in the treatment of epilepsy. Methsuximide suppresses the paroxysmal three cycle per second spike and wave activity associated with lapses of consciousness which is common in absence (petit mal) seizures. The frequency of epileptiform attacks is reduced, apparently by depression of the motor cortex and elevation of the threshold of the central nervous system to convulsive stimuli.
Mechanism of actionBinds to T-type voltage sensitive calcium channels. Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1G gives rise to T-type calcium currents. T-type calcium channels belong to the "low-voltage activated (LVA)" group and are strongly blocked by mibefradil. A particularity of this type of channels is an opening at quite negative potentials and a voltage-dependent inactivation. T-type channels serve pacemaking functions in both central neurons and cardiac nodal cells and support calcium signaling in secretory cells and vascular smooth muscle. They may also be involved in the modulation of firing patterns of neurons which is important for information processing as well as in cell growth processes.
Related Articles
AbsorptionNot Available
Volume of distributionNot Available
Protein bindingNot Available
MetabolismNot Available
Route of eliminationNot Available
Half life1.4-2.6 hours for mesuximide and 28-38 hours for the active metabolite.
ClearanceNot Available
ToxicityAcute overdoses may produce nausea, vomiting, and CNS depression including coma with respiratory depression. Levels greater than 40 µg/mL have caused toxicity and coma has been seen at levels of 150 µg/mL.
Affected organisms
  • Humans and other mammals
PathwaysNot Available
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+1.0
Blood Brain Barrier+0.9967
Caco-2 permeable+0.6968
P-glycoprotein substrateNon-substrate0.7118
P-glycoprotein inhibitor INon-inhibitor0.8599
P-glycoprotein inhibitor IINon-inhibitor0.9433
Renal organic cation transporterNon-inhibitor0.7784
CYP450 2C9 substrateNon-substrate0.7943
CYP450 2D6 substrateNon-substrate0.8923
CYP450 3A4 substrateSubstrate0.6004
CYP450 1A2 substrateNon-inhibitor0.888
CYP450 2C9 inhibitorNon-inhibitor0.8882
CYP450 2D6 inhibitorNon-inhibitor0.922
CYP450 2C19 inhibitorNon-inhibitor0.845
CYP450 3A4 inhibitorNon-inhibitor0.9748
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9629
Ames testNon AMES toxic0.9099
CarcinogenicityNon-carcinogens0.8355
BiodegradationNot ready biodegradable0.8265
Rat acute toxicity2.1961 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9942
hERG inhibition (predictor II)Non-inhibitor0.9625
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
ManufacturersNot Available
Packagers
Dosage forms
FormRouteStrength
Capsuleoral300 mg/1
Capsuleoral300 mg
Prices
Unit descriptionCostUnit
Celontin 300 mg kapseal1.53USD each
Celontin 300 mg Capsule1.1USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
PatentsNot Available
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point52.5 °CPhysProp
boiling point121.5 °C at 1.00E-01 mm HgPhysProp
Predicted Properties
PropertyValueSource
Water Solubility2.13 mg/mLALOGPS
logP1.46ALOGPS
logP1.46ChemAxon
logS-2ALOGPS
pKa (Strongest Acidic)19.03ChemAxon
pKa (Strongest Basic)-7.2ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count0ChemAxon
Polar Surface Area37.38 Å2ChemAxon
Rotatable Bond Count1ChemAxon
Refractivity56.35 m3·mol-1ChemAxon
Polarizability21.4 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
MSMass Spectrum (Electron Ionization)splash10-014i-4910000000-aa3742fc04cdbcda351fView in MoNA
References
Synthesis ReferenceNot Available
General References
  1. Hurst DL: Methsuximide therapy of juvenile myoclonic epilepsy. Seizure. 1996 Mar;5(1):47-50. [PubMed:8777552 ]
  2. Besag FM, Berry DJ, Pool F: Methsuximide lowers lamotrigine blood levels: A pharmacokinetic antiepileptic drug interaction. Epilepsia. 2000 May;41(5):624-7. [PubMed:10802770 ]
External Links
ATC CodesN03AD03
AHFS CodesNot Available
PDB EntriesNot Available
FDA labelNot Available
MSDSNot Available
Interactions
Drug Interactions
Drug
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with Methsuximide.
AbirateroneThe metabolism of Methsuximide can be decreased when combined with Abiraterone.
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with Methsuximide.
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with Methsuximide.
adipiplonThe risk or severity of adverse effects can be increased when adipiplon is combined with Methsuximide.
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with Methsuximide.
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with Methsuximide.
AlfentanilThe risk or severity of adverse effects can be increased when Alfentanil is combined with Methsuximide.
AlphacetylmethadolThe risk or severity of adverse effects can be increased when Alphacetylmethadol is combined with Methsuximide.
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with Methsuximide.
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with Methsuximide.
AmitriptylineThe risk or severity of adverse effects can be increased when Amitriptyline is combined with Methsuximide.
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with Methsuximide.
AmoxapineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Amoxapine.
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with Methsuximide.
AripiprazoleThe risk or severity of adverse effects can be increased when Aripiprazole is combined with Methsuximide.
ArmodafinilThe metabolism of Methsuximide can be decreased when combined with Armodafinil.
ArticaineThe risk or severity of adverse effects can be increased when Articaine is combined with Methsuximide.
AsenapineThe risk or severity of adverse effects can be increased when Asenapine is combined with Methsuximide.
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with Methsuximide.
AzelastineMethsuximide may increase the central nervous system depressant (CNS depressant) activities of Azelastine.
AzelastineThe risk or severity of adverse effects can be increased when Azelastine is combined with Methsuximide.
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with Methsuximide.
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with Methsuximide.
BenzocaineThe risk or severity of adverse effects can be increased when Benzocaine is combined with Methsuximide.
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with Methsuximide.
BortezomibThe metabolism of Methsuximide can be decreased when combined with Bortezomib.
BrexpiprazoleThe risk or severity of adverse effects can be increased when Methsuximide is combined with Brexpiprazole.
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.
BrimonidineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Brimonidine.
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with Methsuximide.
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with Methsuximide.
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with Methsuximide.
BupivacaineThe risk or severity of adverse effects can be increased when Bupivacaine is combined with Methsuximide.
BuprenorphineThe risk or severity of adverse effects can be increased when Buprenorphine is combined with Methsuximide.
BuspironeThe risk or severity of adverse effects can be increased when Buspirone is combined with Methsuximide.
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with Methsuximide.
ButacaineThe risk or severity of adverse effects can be increased when Butacaine is combined with Methsuximide.
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with Methsuximide.
ButambenThe risk or severity of adverse effects can be increased when Butamben is combined with Methsuximide.
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with Methsuximide.
ButorphanolThe risk or severity of adverse effects can be increased when Butorphanol is combined with Methsuximide.
CarbamazepineThe risk or severity of adverse effects can be increased when Carbamazepine is combined with Methsuximide.
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with Methsuximide.
CarfentanilThe risk or severity of adverse effects can be increased when Carfentanil is combined with Methsuximide.
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with Methsuximide.
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with Methsuximide.
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with Methsuximide.
ChloramphenicolThe metabolism of Methsuximide can be decreased when combined with Chloramphenicol.
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Methsuximide.
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with Methsuximide.
ChloroprocaineThe risk or severity of adverse effects can be increased when Chloroprocaine is combined with Methsuximide.
ChlorphenamineThe risk or severity of adverse effects can be increased when Chlorphenamine is combined with Methsuximide.
ChlorpromazineThe risk or severity of adverse effects can be increased when Chlorpromazine is combined with Methsuximide.
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with Methsuximide.
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Methsuximide.
CholecalciferolThe metabolism of Methsuximide can be decreased when combined with Cholecalciferol.
CilostazolThe serum concentration of Cilostazol can be increased when it is combined with Methsuximide.
CimetidineThe metabolism of Methsuximide can be decreased when combined with Cimetidine.
CinchocaineThe risk or severity of adverse effects can be increased when Cinchocaine is combined with Methsuximide.
CitalopramThe risk or severity of adverse effects can be increased when Methsuximide is combined with Citalopram.
CitalopramThe metabolism of Methsuximide can be decreased when combined with Citalopram.
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with Methsuximide.
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with Methsuximide.
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with Methsuximide.
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with Methsuximide.
ClomipramineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Clomipramine.
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with Methsuximide.
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with Methsuximide.
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with Methsuximide.
ClotrimazoleThe metabolism of Methsuximide can be decreased when combined with Clotrimazole.
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with Methsuximide.
CocaineThe risk or severity of adverse effects can be increased when Cocaine is combined with Methsuximide.
CodeineThe risk or severity of adverse effects can be increased when Codeine is combined with Methsuximide.
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with Methsuximide.
CyclobenzaprineThe risk or severity of adverse effects can be increased when Cyclobenzaprine is combined with Methsuximide.
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with Methsuximide.
DabrafenibThe serum concentration of Methsuximide can be decreased when it is combined with Dabrafenib.
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with Methsuximide.
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with Methsuximide.
DapoxetineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Dapoxetine.
DelavirdineThe metabolism of Methsuximide can be decreased when combined with Delavirdine.
deramciclaneThe risk or severity of adverse effects can be increased when deramciclane is combined with Methsuximide.
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with Methsuximide.
DesipramineThe risk or severity of adverse effects can be increased when Desipramine is combined with Methsuximide.
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with Methsuximide.
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with Methsuximide.
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Methsuximide.
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with Methsuximide.
DextromoramideThe risk or severity of adverse effects can be increased when Dextromoramide is combined with Methsuximide.
DextropropoxypheneThe risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Methsuximide.
DezocineThe risk or severity of adverse effects can be increased when Dezocine is combined with Methsuximide.
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with Methsuximide.
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with Methsuximide.
DihydrocodeineThe risk or severity of adverse effects can be increased when Dihydrocodeine is combined with Methsuximide.
DihydroetorphineThe risk or severity of adverse effects can be increased when Dihydroetorphine is combined with Methsuximide.
DihydromorphineThe risk or severity of adverse effects can be increased when Dihydromorphine is combined with Methsuximide.
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with Methsuximide.
DiphenhydramineThe risk or severity of adverse effects can be increased when Diphenhydramine is combined with Methsuximide.
DiphenoxylateThe risk or severity of adverse effects can be increased when Diphenoxylate is combined with Methsuximide.
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with Methsuximide.
DoxepinThe risk or severity of adverse effects can be increased when Doxepin is combined with Methsuximide.
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.
DoxylamineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Doxylamine.
DPDPEThe risk or severity of adverse effects can be increased when DPDPE is combined with Methsuximide.
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.
DroperidolThe risk or severity of adverse effects can be increased when Droperidol is combined with Methsuximide.
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with Methsuximide.
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with Methsuximide.
EcgonineThe risk or severity of adverse effects can be increased when Ecgonine is combined with Methsuximide.
ECGONINE METHYL ESTERThe risk or severity of adverse effects can be increased when ECGONINE METHYL ESTER is combined with Methsuximide.
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with Methsuximide.
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with Methsuximide.
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with Methsuximide.
EscitalopramThe risk or severity of adverse effects can be increased when Methsuximide is combined with Escitalopram.
Eslicarbazepine acetateThe metabolism of Methsuximide can be decreased when combined with Eslicarbazepine acetate.
EsomeprazoleThe metabolism of Methsuximide can be decreased when combined with Esomeprazole.
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with Methsuximide.
EszopicloneThe risk or severity of adverse effects can be increased when Eszopiclone is combined with Methsuximide.
EthanolMethsuximide may increase the central nervous system depressant (CNS depressant) activities of Ethanol.
EthanolThe risk or severity of adverse effects can be increased when Ethanol is combined with Methsuximide.
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Methsuximide.
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with Methsuximide.
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with Methsuximide.
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with Methsuximide.
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with Methsuximide.
EthylmorphineThe risk or severity of adverse effects can be increased when Ethylmorphine is combined with Methsuximide.
EtidocaineThe risk or severity of adverse effects can be increased when Etidocaine is combined with Methsuximide.
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with Methsuximide.
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with Methsuximide.
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with Methsuximide.
EtoperidoneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Etoperidone.
EtorphineThe risk or severity of adverse effects can be increased when Etorphine is combined with Methsuximide.
EtravirineThe metabolism of Methsuximide can be decreased when combined with Etravirine.
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with Methsuximide.
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with Methsuximide.
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with Methsuximide.
FenfluramineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Fenfluramine.
FentanylThe risk or severity of adverse effects can be increased when Fentanyl is combined with Methsuximide.
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with Methsuximide.
FlibanserinThe risk or severity of adverse effects can be increased when Flibanserin is combined with Methsuximide.
FluconazoleThe metabolism of Methsuximide can be decreased when combined with Fluconazole.
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with Methsuximide.
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with Methsuximide.
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with Methsuximide.
FluoxetineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Fluoxetine.
FluoxetineThe metabolism of Methsuximide can be decreased when combined with Fluoxetine.
FlupentixolThe risk or severity of adverse effects can be increased when Flupentixol is combined with Methsuximide.
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with Methsuximide.
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with Methsuximide.
FluspirileneThe risk or severity of adverse effects can be increased when Fluspirilene is combined with Methsuximide.
Fluticasone PropionateThe risk or severity of adverse effects can be increased when Fluticasone Propionate is combined with Methsuximide.
FluvoxamineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Fluvoxamine.
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with Methsuximide.
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with Methsuximide.
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with Methsuximide.
gabapentin enacarbilThe risk or severity of adverse effects can be increased when Methsuximide is combined with gabapentin enacarbil.
Gamma Hydroxybutyric AcidThe risk or severity of adverse effects can be increased when Gamma Hydroxybutyric Acid is combined with Methsuximide.
GemfibrozilThe metabolism of Methsuximide can be decreased when combined with Gemfibrozil.
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with Methsuximide.
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with Methsuximide.
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with Methsuximide.
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with Methsuximide.
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with Methsuximide.
HeroinThe risk or severity of adverse effects can be increased when Heroin is combined with Methsuximide.
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with Methsuximide.
HydrocodoneThe risk or severity of adverse effects can be increased when Hydrocodone is combined with Methsuximide.
HydromorphoneThe risk or severity of adverse effects can be increased when Hydromorphone is combined with Methsuximide.
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.
HydroxyzineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Hydroxyzine.
IloperidoneThe risk or severity of adverse effects can be increased when Iloperidone is combined with Methsuximide.
ImipramineThe risk or severity of adverse effects can be increased when Imipramine is combined with Methsuximide.
IndalpineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Indalpine.
IndinavirThe metabolism of Methsuximide can be decreased when combined with Indinavir.
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with Methsuximide.
IsoniazidThe metabolism of Methsuximide can be decreased when combined with Isoniazid.
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with Methsuximide.
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with Methsuximide.
KetobemidoneThe risk or severity of adverse effects can be increased when Ketobemidone is combined with Methsuximide.
KetoconazoleThe metabolism of Methsuximide can be decreased when combined with Ketoconazole.
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with Methsuximide.
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with Methsuximide.
LevobupivacaineThe risk or severity of adverse effects can be increased when Levobupivacaine is combined with Methsuximide.
LevocabastineThe risk or severity of adverse effects can be increased when Levocabastine is combined with Methsuximide.
LevocetirizineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Levocetirizine.
LevodopaThe risk or severity of adverse effects can be increased when Levodopa is combined with Methsuximide.
Levomethadyl AcetateThe risk or severity of adverse effects can be increased when Levomethadyl Acetate is combined with Methsuximide.
LevomilnacipranThe risk or severity of adverse effects can be increased when Methsuximide is combined with Levomilnacipran.
LevorphanolThe risk or severity of adverse effects can be increased when Levorphanol is combined with Methsuximide.
LidocaineThe risk or severity of adverse effects can be increased when Lidocaine is combined with Methsuximide.
LithiumThe risk or severity of adverse effects can be increased when Lithium is combined with Methsuximide.
LofentanilThe risk or severity of adverse effects can be increased when Lofentanil is combined with Methsuximide.
LopinavirThe metabolism of Methsuximide can be increased when combined with Lopinavir.
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with Methsuximide.
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with Methsuximide.
LoxapineThe risk or severity of adverse effects can be increased when Loxapine is combined with Methsuximide.
Lu AA21004The risk or severity of adverse effects can be increased when Methsuximide is combined with Lu AA21004.
LuliconazoleThe serum concentration of Methsuximide can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Methsuximide can be decreased when it is combined with Lumacaftor.
LurasidoneThe risk or severity of adverse effects can be increased when Lurasidone is combined with Methsuximide.
Magnesium SulfateMagnesium Sulfate may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.
Magnesium SulfateThe risk or severity of adverse effects can be increased when Methsuximide is combined with Magnesium Sulfate.
MaprotilineThe risk or severity of adverse effects can be increased when Maprotiline is combined with Methsuximide.
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with Methsuximide.
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with Methsuximide.
MefloquineThe therapeutic efficacy of Methsuximide can be decreased when used in combination with Mefloquine.
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with Methsuximide.
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with Methsuximide.
MepivacaineThe risk or severity of adverse effects can be increased when Mepivacaine is combined with Methsuximide.
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with Methsuximide.
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with Methsuximide.
MetaxaloneThe risk or severity of adverse effects can be increased when Metaxalone is combined with Methsuximide.
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with Methsuximide.
Methadyl AcetateThe risk or severity of adverse effects can be increased when Methadyl Acetate is combined with Methsuximide.
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with Methsuximide.
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with Methsuximide.
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with Methsuximide.
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with Methsuximide.
MethotrimeprazineThe risk or severity of adverse effects can be increased when Methotrimeprazine is combined with Methsuximide.
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with Methsuximide.
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Methsuximide.
MetyrosineMethsuximide may increase the sedative activities of Metyrosine.
MianserinThe therapeutic efficacy of Methsuximide can be decreased when used in combination with Mianserin.
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with Methsuximide.
MilnacipranThe risk or severity of adverse effects can be increased when Methsuximide is combined with Milnacipran.
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.
MirtazapineMethsuximide may increase the central nervous system depressant (CNS depressant) activities of Mirtazapine.
MirtazapineThe risk or severity of adverse effects can be increased when Mirtazapine is combined with Methsuximide.
MoclobemideThe metabolism of Methsuximide can be decreased when combined with Moclobemide.
ModafinilThe metabolism of Methsuximide can be decreased when combined with Modafinil.
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with Methsuximide.
MorphineThe risk or severity of adverse effects can be increased when Morphine is combined with Methsuximide.
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of Methsuximide.
NabiloneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Nabilone.
NalbuphineThe risk or severity of adverse effects can be increased when Nalbuphine is combined with Methsuximide.
NelfinavirThe metabolism of Methsuximide can be decreased when combined with Nelfinavir.
NicardipineThe metabolism of Methsuximide can be decreased when combined with Nicardipine.
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with Methsuximide.
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with Methsuximide.
NormethadoneThe risk or severity of adverse effects can be increased when Normethadone is combined with Methsuximide.
NortriptylineThe risk or severity of adverse effects can be increased when Nortriptyline is combined with Methsuximide.
OlanzapineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Olanzapine.
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with Methsuximide.
OmeprazoleThe metabolism of Methsuximide can be decreased when combined with Omeprazole.
OndansetronThe risk or severity of adverse effects can be increased when Ondansetron is combined with Methsuximide.
OpiumThe risk or severity of adverse effects can be increased when Opium is combined with Methsuximide.
OrlistatThe serum concentration of Methsuximide can be decreased when it is combined with Orlistat.
OrphenadrineMethsuximide may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.
OrphenadrineThe risk or severity of adverse effects can be increased when Orphenadrine is combined with Methsuximide.
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with Methsuximide.
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with Methsuximide.
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with Methsuximide.
OxybuprocaineThe risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Methsuximide.
OxycodoneThe risk or severity of adverse effects can be increased when Oxycodone is combined with Methsuximide.
OxymorphoneThe risk or severity of adverse effects can be increased when Oxymorphone is combined with Methsuximide.
PaliperidoneThe risk or severity of adverse effects can be increased when Paliperidone is combined with Methsuximide.
PantoprazoleThe metabolism of Methsuximide can be decreased when combined with Pantoprazole.
ParaldehydeMethsuximide may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.
ParaldehydeThe risk or severity of adverse effects can be increased when Paraldehyde is combined with Methsuximide.
ParoxetineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Paroxetine.
PentazocineThe risk or severity of adverse effects can be increased when Pentazocine is combined with Methsuximide.
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with Methsuximide.
PerampanelThe risk or severity of adverse effects can be increased when Methsuximide is combined with Perampanel.
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with Methsuximide.
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with Methsuximide.
PethidineThe risk or severity of adverse effects can be increased when Pethidine is combined with Methsuximide.
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with Methsuximide.
PhenoxyethanolThe risk or severity of adverse effects can be increased when Phenoxyethanol is combined with Methsuximide.
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with Methsuximide.
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with Methsuximide.
PipamperoneThe risk or severity of adverse effects can be increased when Pipamperone is combined with Methsuximide.
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with Methsuximide.
PizotifenThe risk or severity of adverse effects can be increased when Methsuximide is combined with Pizotifen.
PomalidomideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Pomalidomide.
PramipexoleMethsuximide may increase the sedative activities of Pramipexole.
PramocaineThe risk or severity of adverse effects can be increased when Pramocaine is combined with Methsuximide.
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with Methsuximide.
PregabalinThe risk or severity of adverse effects can be increased when Pregabalin is combined with Methsuximide.
PrilocaineThe risk or severity of adverse effects can be increased when Prilocaine is combined with Methsuximide.
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with Methsuximide.
ProcaineThe risk or severity of adverse effects can be increased when Procaine is combined with Methsuximide.
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with Methsuximide.
PromazineThe risk or severity of adverse effects can be increased when Promazine is combined with Methsuximide.
PromethazineThe risk or severity of adverse effects can be increased when Promethazine is combined with Methsuximide.
ProparacaineThe risk or severity of adverse effects can be increased when Proparacaine is combined with Methsuximide.
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with Methsuximide.
PropoxycaineThe risk or severity of adverse effects can be increased when Propoxycaine is combined with Methsuximide.
ProtriptylineThe risk or severity of adverse effects can be increased when Protriptyline is combined with Methsuximide.
PSD502The risk or severity of adverse effects can be increased when PSD502 is combined with Methsuximide.
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with Methsuximide.
QuetiapineThe risk or severity of adverse effects can be increased when Quetiapine is combined with Methsuximide.
RamelteonThe risk or severity of adverse effects can be increased when Ramelteon is combined with Methsuximide.
RemifentanilThe risk or severity of adverse effects can be increased when Remifentanil is combined with Methsuximide.
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with Methsuximide.
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with Methsuximide.
RifampicinThe metabolism of Methsuximide can be increased when combined with Rifampicin.
RisperidoneThe risk or severity of adverse effects can be increased when Risperidone is combined with Methsuximide.
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with Methsuximide.
RopiniroleMethsuximide may increase the sedative activities of Ropinirole.
RopivacaineThe risk or severity of adverse effects can be increased when Ropivacaine is combined with Methsuximide.
RotigotineMethsuximide may increase the sedative activities of Rotigotine.
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with Methsuximide.
S-EthylisothioureaThe risk or severity of adverse effects can be increased when S-Ethylisothiourea is combined with Methsuximide.
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with Methsuximide.
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with Methsuximide.
SertindoleThe risk or severity of adverse effects can be increased when Sertindole is combined with Methsuximide.
SertralineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Sertraline.
SertralineThe metabolism of Methsuximide can be decreased when combined with Sertraline.
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with Methsuximide.
Sodium oxybateThe risk or severity of adverse effects can be increased when Sodium oxybate is combined with Methsuximide.
StiripentolThe risk or severity of adverse effects can be increased when Methsuximide is combined with Stiripentol.
SufentanilThe risk or severity of adverse effects can be increased when Sufentanil is combined with Methsuximide.
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with Methsuximide.
SuvorexantThe risk or severity of adverse effects can be increased when Methsuximide is combined with Suvorexant.
TapentadolThe risk or severity of adverse effects can be increased when Methsuximide is combined with Tapentadol.
TasimelteonThe risk or severity of adverse effects can be increased when Methsuximide is combined with Tasimelteon.
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with Methsuximide.
TetrabenazineThe risk or severity of adverse effects can be increased when Tetrabenazine is combined with Methsuximide.
TetracaineThe risk or severity of adverse effects can be increased when Tetracaine is combined with Methsuximide.
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with Methsuximide.
ThalidomideMethsuximide may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.
ThalidomideThe risk or severity of adverse effects can be increased when Thalidomide is combined with Methsuximide.
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with Methsuximide.
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with Methsuximide.
ThioridazineThe risk or severity of adverse effects can be increased when Thioridazine is combined with Methsuximide.
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with Methsuximide.
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with Methsuximide.
TiclopidineThe metabolism of Methsuximide can be decreased when combined with Ticlopidine.
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with Methsuximide.
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with Methsuximide.
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with Methsuximide.
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with Methsuximide.
TramadolThe risk or severity of adverse effects can be increased when Tramadol is combined with Methsuximide.
Trans-2-PhenylcyclopropylamineThe risk or severity of adverse effects can be increased when Trans-2-Phenylcyclopropylamine is combined with Methsuximide.
TranylcypromineThe risk or severity of adverse effects can be increased when Tranylcypromine is combined with Methsuximide.
TrazodoneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Trazodone.
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with Methsuximide.
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with Methsuximide.
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with Methsuximide.
TrimipramineThe risk or severity of adverse effects can be increased when Trimipramine is combined with Methsuximide.
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with Methsuximide.
Valproic AcidThe risk or severity of adverse effects can be increased when Valproic Acid is combined with Methsuximide.
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with Methsuximide.
VilazodoneThe risk or severity of adverse effects can be increased when Methsuximide is combined with Vilazodone.
VoriconazoleThe metabolism of Methsuximide can be decreased when combined with Voriconazole.
VortioxetineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Vortioxetine.
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with Methsuximide.
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with Methsuximide.
ZiconotideThe risk or severity of adverse effects can be increased when Methsuximide is combined with Ziconotide.
ZimelidineThe risk or severity of adverse effects can be increased when Methsuximide is combined with Zimelidine.
ZiprasidoneThe risk or severity of adverse effects can be increased when Ziprasidone is combined with Methsuximide.
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with Methsuximide.
ZolpidemThe risk or severity of adverse effects can be increased when Zolpidem is combined with Methsuximide.
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with Methsuximide.
ZopicloneThe risk or severity of adverse effects can be increased when Zopiclone is combined with Methsuximide.
ZotepineThe risk or severity of adverse effects can be increased when Zotepine is combined with Methsuximide.
ZuclopenthixolThe risk or severity of adverse effects can be increased when Zuclopenthixol is combined with Methsuximide.
Food Interactions
  • Avoid alcohol
  • Take with food

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
inhibitor
General Function:
Scaffold protein binding
Specific Function:
Voltage-sensitive calcium channels (VSCC) mediate the entry of calcium ions into excitable cells and are also involved in a variety of calcium-dependent processes, including muscle contraction, hormone or neurotransmitter release, gene expression, cell motility, cell division and cell death. The isoform alpha-1G gives rise to T-type calcium currents. T-type calcium channels belong to the "low-v...
Gene Name:
CACNA1G
Uniprot ID:
O43497
Molecular Weight:
262468.62 Da
References
  1. Gomora JC, Daud AN, Weiergraber M, Perez-Reyes E: Block of cloned human T-type calcium channels by succinimide antiepileptic drugs. Mol Pharmacol. 2001 Nov;60(5):1121-32. [PubMed:11641441 ]
  2. Coulter DA, Huguenard JR, Prince DA: Characterization of ethosuximide reduction of low-threshold calcium current in thalamic neurons. Ann Neurol. 1989 Jun;25(6):582-93. [PubMed:2545161 ]
  3. Wang G, Thompson SM: Maladaptive homeostatic plasticity in a rodent model of central pain syndrome: thalamic hyperexcitability after spinothalamic tract lesions. J Neurosci. 2008 Nov 12;28(46):11959-69. doi: 10.1523/JNEUROSCI.3296-08.2008. [PubMed:19005061 ]
  4. Matthews EA, Dickenson AH: Effects of ethosuximide, a T-type Ca(2+) channel blocker, on dorsal horn neuronal responses in rats. Eur J Pharmacol. 2001 Mar;415(2-3):141-9. [PubMed:11274992 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Responsible for the metabolism of a number of therapeutic agents such as the anticonvulsant drug S-mephenytoin, omeprazole, proguanil, certain barbiturates, diazepam, propranolol, citalopram and imipramine.
Gene Name:
CYP2C19
Uniprot ID:
P33261
Molecular Weight:
55930.545 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Comments
comments powered by Disqus
Drug created on October 30, 2007 19:03 / Updated on August 17, 2016 12:24